We therefore assessed SOAT1 expression by immunohistochemistry in tumor tissue from patients with GBM and IDH-mutant astrocytoma, CNS WHO grade 4 (HGA), using normal brain as a control that could also be relevant for the observed neurotoxic side effects of SOAT1 inhibitors such as mitotane. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).